Diagnostic utility of CD56 in differentiating papillary thyroid carcinoma from other lesions of thyroid
العنوان: | Diagnostic utility of CD56 in differentiating papillary thyroid carcinoma from other lesions of thyroid |
---|---|
المؤلفون: | Syeda Khadija Fatima, Khatija Shameem, Bhavani Myla |
المصدر: | Indian Journal of Pathology and Oncology. 7:582-589 |
بيانات النشر: | IP Innovative Publication Pvt Ltd, 2020. |
سنة النشر: | 2020 |
مصطلحات موضوعية: | endocrine system, medicine.medical_specialty, Pathology, endocrine system diseases, Clinical pathology, business.industry, medicine.medical_treatment, Thyroid, Thyroidectomy, 030209 endocrinology & metabolism, medicine.disease, Surgical pathology, Thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, medicine, Biomarker (medicine), Immunohistochemistry, business, Thyroid cancer |
الوصف: | Background: Thyroid cancer is one of the most common malignant neoplasm worldwide. Among Indians, thyroid cancer constitutes 3.96% of total cancers. Papillary thyroid carcinoma (PTC) is a malignant epithelial tumor with distinctive nuclear features. PTC represents, about 85% of all malignant thyroid neoplasm. Though histopathological diagnosis is the gold standard for PTC diagnosis, pathologists usually face difficulty due to morphologic overlap between follicular neoplasms and PTC, especially the follicular variant of PTC. CD56 is a neuroendocrine marker and an antigen important for the follicular epithelium differentiation. Recent studies have reported low or absent expression of CD56 in PTC and its presence in normal thyroid tissue, benign thyroid lesions, and most follicular non-PTC tumors. Aims: This study aimed to assess the diagnostic utility of immunohistochemical marker, CD56 in distinguishing PTC from benign thyroid lesions and follicular neoplasms. Materials and Methods: This was a prospective and retrospective case control study conducted at department of Pathology of our institute. All 125 thyroidectomy specimens received during a study period from January 2017 to December 2019 were studied and any already established recurrent case of PTC was excluded. After routine histopathological examination, the expression of CD56 was studied and statistically analyzed. Results: The difference between expression of CD56 antibody in differentiating PTC from other thyroid lesions was found to be statistically significant (p= specificity was 97.7%. Conclusion: Thus, CD56 was found to be a valuable and sensitive biomarker even when used individually. Keywords: CD56, Immunohistochemistry, Papillary carcinoma of thyroid, Follicular variant of papillary thyroid carcinoma. |
تدمد: | 2394-6792 2394-6784 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::f24fe980f8b53f20ffe2d2a191bca8da https://doi.org/10.18231/j.ijpo.2020.116 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi...........f24fe980f8b53f20ffe2d2a191bca8da |
قاعدة البيانات: | OpenAIRE |
تدمد: | 23946792 23946784 |
---|